Risedronate Sodium in Post Menopausal Osteoporosis
|ClinicalTrials.gov Identifier: NCT00453492|
Recruitment Status : Completed
First Posted : March 29, 2007
Last Update Posted : March 11, 2008
The primary objective is to compare subject satisfaction of once a week dosing of 35 mg Actonel to once daily dosing of 5 mg Actonel in postmenopausal osteoporotic women.
The secondary objectives are to measure compliance (50 % drug taken), and persistence, [and urinary NTx (N-telopeptides) (optional)].
|Condition or disease||Intervention/treatment||Phase|
|Osteoporosis, Postmenopausal||Drug: risedronate sodium||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||246 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily|
|Study Start Date :||January 2004|
- Measurement of subject satisfaction using a questionnaire at 12 and 24 weeks and a tablets counts at 12 and 24 weeks.
- Optional: the effects of Actonel on bone resorption will be assessed by a change of urinary NTx, after 12 and 24 weeks of treatment as compared to baseline.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00453492
|Study Director:||Edibe Taylan||Sanofi-aventis, Turkey|